Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
13.16
+0.18 (+1.39%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about REGENXBIO Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023
↗
June 20, 2023
Via
Benzinga
The Latest Analyst Ratings for Regenxbio
↗
June 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
↗
June 02, 2023
Via
Benzinga
Regenxbio's Return On Capital Employed Insights
↗
May 11, 2023
Via
Benzinga
Analyst Expectations for Regenxbio's Future
↗
May 09, 2023
Via
Benzinga
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 16, 2023
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.
Via
Benzinga
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
↗
April 15, 2023
The company focuses on using its technology for gene-editing therapies.
Via
The Motley Fool
Earnings Preview: Regenxbio
↗
February 27, 2023
Via
Benzinga
Looking Into Regenxbio's Return On Capital Employed
↗
November 22, 2022
Via
Benzinga
5 Analysts Have This to Say About Regenxbio
↗
November 21, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About Regenxbio
↗
November 04, 2022
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:
Via
Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
↗
November 03, 2022
Via
Benzinga
Tesla To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Monday
↗
March 06, 2023
Citigroup raised the price target for The Manitowoc Company, Inc. (NYSE: MTW) from $11 to $21. Citigroup analyst Timothy Thein maintained a Neutral rating. Manitowoc shares fell 2.4% to $19.09 in...
Via
Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
↗
March 01, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Regenxbio's Earnings Outlook
↗
November 02, 2022
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...
Via
Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
↗
October 04, 2022
B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
↗
September 09, 2022
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:
Via
Benzinga
4 Analysts Have This to Say About Regenxbio
↗
August 10, 2022
Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Earnings Scheduled For February 28, 2023
↗
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Recap: Regenxbio Q3 Earnings
↗
November 03, 2022
Regenxbio (NASDAQ:RGNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
↗
October 04, 2022
Via
Benzinga
Expert Ratings for Regenxbio
↗
June 23, 2022
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:
Via
Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
↗
August 03, 2022
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
↗
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For November 3, 2022
↗
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Regenxbio's Earnings Outlook
↗
August 02, 2022
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
↗
June 23, 2022
Upgrades
Via
Benzinga
5 Small-Cap S&P Stocks To Buy With The Most Upside
↗
May 26, 2022
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than...
Via
Benzinga
Regenxbio's Return On Capital Employed Overview
↗
May 24, 2022
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.